Bristol-Myers Squibb

This phase 2 trial tests a drug called navlimetostat in about 130 people with advanced or metastatic non-small cell lung cancer that has a specific genetic change (MTAP deletion) and has worsened after other treatments. The main goal is to see if the drug can shrink tumors. Resea…

This study tests whether a combination of two drugs, KarXT and KarX-EC, can improve cognitive impairment in people with mild to moderate Alzheimer's disease. About 586 participants will receive either the drug combo or a placebo. The trial measures changes in thinking, daily func…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This phase 2 trial tests whether adding two experimental drugs, imzokitug and pumitamig, to standard chemotherapy helps people with advanced non-small cell lung cancer (NSCLC) who have not had prior treatment. About 160 participants will receive either the three-drug combination …

This study tests a new drug called pumitamig, alone or with another drug (ipilimumab), in people with advanced liver cancer that cannot be removed by surgery. The trial includes 198 participants who have not had prior cancer treatment. The goal is to see if the drugs are safe and…

This study tests an experimental drug called BMS-986525, given alone or with the immunotherapy nivolumab (Opdivo), in 240 people whose small cell lung cancer has returned or stopped responding to standard platinum-based chemotherapy. The main goals are to check safety and tolerab…

This phase 3 trial is testing whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of…

This study tests a new drug called pumitamig, alone or combined with ipilimumab or cabozantinib, in 254 people with advanced kidney cancer that cannot be removed by surgery. The goal is to see if the drug is safe and can shrink tumors. Participants must have a confirmed diagnosis…

This study tests whether adding a new drug called navlimetostat to standard immunotherapy (pembrolizumab) and chemotherapy helps people with a specific genetic form of advanced lung cancer (MTAP deletion) live longer without their cancer worsening. About 590 participants will be …

This study tests a new drug called BMS-986507, alone or with other cancer medicines, in adults with advanced lung or breast cancer that has spread. The goal is to check safety, side effects, and how well the drugs work. About 416 participants will receive different combinations t…

This phase 3 study is testing the long-term safety of KarXT, a new drug for managing mania in people with bipolar I disorder. About 450 participants, including those who completed earlier studies and new volunteers, will take KarXT along with standard mood stabilizers like lithiu…

This study tests a new drug called BMS-986458, which works by breaking down a protein that helps lymphoma cells grow. It is being tested alone or with other lymphoma drugs in people whose non-Hodgkin lymphoma has returned or not responded to prior treatments. The trial aims to fi…

This study tests whether a new drug called pumitamig, combined with chemotherapy, works better than the current standard treatment (bevacizumab plus chemo) for people with advanced colorectal cancer that cannot be removed by surgery. About 990 adults who have not yet been treated…

This phase 3 trial is testing a new combination of drugs (BMS-986489) plus chemotherapy against a standard treatment (atezolizumab plus chemotherapy) for people with extensive-stage small cell lung cancer, a fast-growing cancer. The study aims to see if the new combo helps people…

This study compares two daily pills, ozanimod and fingolimod, to see which works better at preventing MS relapses in children and teens aged 10 to 17. Participants will be randomly assigned to one of the two drugs and monitored for about two years. The goal is to find a more effe…

This study offers continued treatment with deucravacitinib for people with systemic lupus erythematosus (SLE) or related skin lupus who finished earlier trials. It aims to keep the disease under control by providing ongoing access to the medication. Only 35 participants are being…

This phase 3 trial compares a new drug called pumitamig to the standard drug pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1 (at least 50%). The study will enroll 750 participants and measure ho…

This phase 3 study compares the experimental drug pumitamig to the standard treatment durvalumab in people with stage III lung cancer that cannot be removed by surgery. Participants must have finished chemoradiation without their cancer getting worse. The main goal is to see if p…

This study compares two drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that hasn't been treated yet. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combo works b…

This Phase 3 study tests whether KarXT, a combination of two drugs, can safely reduce manic symptoms in people with Bipolar-I disorder. About 274 participants hospitalized for mania will receive either KarXT or a placebo. The main goal is to see if KarXT improves scores on a stan…

This phase 3 trial is testing whether the drug KarXT can safely and effectively treat schizophrenia in adolescents aged 13 to 17. About 166 teens will receive either KarXT or a placebo, and researchers will track changes in symptoms like delusions and social withdrawal. The goal …

This study tests a daily pill called deucravacitinib in teenagers aged 12 to 18 with moderate to severe plaque psoriasis. About 366 participants will receive either the drug or a placebo. The main goals are to see if the drug improves skin clearance by at least 75% and reduces ov…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This early-stage study is testing a long-acting injectable form of the drug KarXT in 116 people with schizophrenia. The main goal is to check the drug's safety and how the body processes it. Researchers hope this injectable version could offer a more convenient treatment option t…

This study tests whether switching teen kidney transplant recipients (ages 12-17) from standard immunosuppressants (calcineurin inhibitors) to belatacept (Nulojix) can improve kidney function and medication adherence. About 102 teens who received a kidney transplant at least 6 mo…

This study tests a new drug called izalontamab brengitecan against standard chemotherapy in 500 people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that has stopped responding to current targeted pills. The goal is to see if the new drug can delay…

This early-stage study tests a new drug, BMS-986528, in 84 adults with rheumatoid arthritis that hasn't responded well to other treatments. The main goal is to check safety and how the body processes the drug. Researchers will also look for signs that it might help control the di…

This study tests the long-term safety of deucravacitinib compared to ustekinumab in about 3,040 adults with moderate-to-severe plaque psoriasis who also have heart risk factors like smoking, high blood pressure, or diabetes. Participants will receive one of the two medications an…

This study tests a drug called deucravacitinib in children aged 5 to 17 with active juvenile psoriatic arthritis, a condition causing joint pain and swelling. The trial aims to see if the drug can control the disease and prevent flare-ups. About 60 participants will receive eithe…

This study is testing a drug called luspatercept in adults with a severe blood disorder called beta-thalassemia who need regular blood transfusions. The goal is to see if the drug can reduce how many transfusions they need and improve their hemoglobin levels. Researchers will fol…

This study is tracking 300 adults with schizophrenia in the U.S. who are prescribed a new drug called xanomeline and trospium chloride (X/T). Researchers want to know if patients prefer this drug over their previous treatment and how satisfied they are with it. The study will als…

This study tracks 1,500 adults with schizophrenia who start taking KarXT (xanomeline and trospium chloride) in routine clinical care across the U.S. Researchers will monitor how doctors adjust doses, side effects, weight changes, and relapses over time. The goal is to understand …

This study tests a new drug called BMS-986470 in healthy volunteers and people with sickle cell disease. The goal is to check its safety, how the body processes it, and whether it might help control the disease. The trial is in early phases and involves about 184 participants.

This study tests a drug called deucravacitinib in children and teens aged 4 to 18 with moderate to severe plaque psoriasis. The trial will measure how the drug works in the body, how well it clears psoriasis, and its safety over up to 5 years. Participants are randomly assigned t…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This early-stage study tests a new drug, BMS-986506, in people with advanced clear cell kidney cancer that has not responded to prior treatments. The main goal is to check the drug's safety and how well the body tolerates it. About 125 participants will take the drug alone to see…

This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …

This early-stage trial is testing a new drug called BMS-986460 in 140 men with metastatic castration-resistant prostate cancer, a type that no longer responds to standard hormone therapy. The main goals are to check the drug's safety and find the right dose, while also looking fo…

This study tests a new drug called izalontamab brengitecan (BMS-986507) against standard chemotherapy in about 500 people with advanced triple-negative or ER-low breast cancer who cannot receive immunotherapy. The drug is designed to target and kill cancer cells while sparing hea…

This study monitors the safety of repotrectinib, a targeted cancer drug, in children and adolescents aged 4 to under 18 with NTRK fusion-positive advanced or recurrent solid tumors. Researchers will track side effects during routine treatment, paying special attention to nervous …

This study offers long-term treatment with nivolumab and other cancer therapies to 1,500 patients who previously benefited from Bristol-Myers Squibb trials. The main goal is to monitor safety and side effects over time. Participants must have had a good response in their earlier …

This early-stage trial is testing an experimental drug called BMS-986488, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 437 adults w…

This study compares a new drug, izalontamab brengitecan, against standard platinum-based chemotherapy in 470 people with metastatic urothelial cancer that has worsened after immunotherapy. The goal is to see if the new drug can slow cancer growth or improve survival. Participants…

This phase 3 study tests whether KarXT, a new drug, can safely reduce schizophrenia symptoms in 250 Japanese adults experiencing acute psychosis. Participants first receive either KarXT or a placebo for 5 weeks, then all may receive KarXT for a year. The goal is to see if KarXT i…

This study tests an oral medication called ozanimod in children aged 12-17 with moderate-to-severe ulcerative colitis who haven't responded to standard treatments. The goal is to see if the drug can safely bring the disease into remission. About 120 participants will receive eith…

This early-phase trial is testing a new drug called BMS-986454 in 46 adults with rheumatoid arthritis who did not fully respond to methotrexate. The main goal is to check the drug's safety, tolerability, and how it moves through the body. Participants will receive either the drug…

This early-phase study tests a new drug called BMS-986463 in people with advanced ovarian, uterine, or lung cancer that has spread or cannot be removed by surgery. The main goals are to check safety and find the best dose. About 240 participants will receive the drug, and researc…

This early-stage trial is testing an experimental drug called BMS-986500 in people with advanced solid tumors or breast cancer that has not responded to prior treatments. The study will first test the drug alone, then in combination with other cancer drugs (palbociclib and fulves…

This study observes how a combination of two immunotherapy drugs, nivolumab and ipilimumab, works for people with advanced liver cancer that cannot be removed by surgery. It follows adults receiving this treatment as part of their routine medical care in Japan to understand its s…

This study is testing a drug called mavacamten in adults with a type of heart disease called obstructive hypertrophic cardiomyopathy (HOCM) in Japan. The goal is to see if mavacamten can improve heart function and symptoms when added to their current treatment. About 36 participa…

This study tests whether adding KarXT to standard mood stabilizers (lithium, valproate, or lamotrigine) helps control manic episodes in people with bipolar I disorder. About 424 adults hospitalized for mania will receive either KarXT or a placebo for 5 weeks. The main goal is to …

This study looks at how well the drug mavacamten works for Chinese adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is too thick. About 500 people will be followed in regular clinic settings. The main goal is to see if the drug improves bloo…

This study is testing how the drug KarXT affects bladder function and overall safety in 60 adults with schizophrenia over 12 months. Participants will stop their current antipsychotics and take KarXT to see if it causes any urinary problems. The goal is to ensure the drug is safe…

This early-stage study tests a new drug called navlimetostat in 32 Japanese and Chinese patients with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goal is to check the drug's safety and how the body processes it. Participants must have tumor…

This study tests a new drug called BMS-986523, alone or with other cancer drugs, in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change (KRAS mutation). The goal is to see if it is safe and works. About 252 adults wi…

This study follows 350 adults in France with moderate-to-severe plaque psoriasis who are starting deucravacitinib, a daily pill. Researchers will track how well the drug controls skin symptoms and improves quality of life over time in real-world settings, not a controlled lab env…

This study looks at how well ozanimod works compared to azathioprine for people with steroid-dependent ulcerative colitis in Japan. Researchers will review medical records of 150 adults to see which drug helps patients stop steroids and stay symptom-free. The goal is to find a be…

This early-stage study tests a new drug, BMS-986497, in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not improved after prior treatments. The drug is given alone or combined with standard medicines (azacitidine and venetoclax). T…

This program offers expanded access to iberdomide for people who have no other treatment options. It is designed to provide the drug to eligible participants outside of a clinical trial. The goal is to make this medication available to those who may benefit from it.

This study tests an experimental drug called BMS-986482, alone or combined with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 413 adults will take part. Th…

This study monitors the real-world safety and effectiveness of mavacamten in about 200 people in Japan who have obstructive hypertrophic cardiomyopathy, a condition where the heart muscle thickens and blocks blood flow. Participants will be followed to track any side effects and …

This program offers expanded access to mezigdomide for eligible participants who have no other treatment options. The goal is to provide this medication to those who may benefit from it. Participants must meet specific criteria to join.

This study follows 200 Italian patients with moderate-to-severe psoriasis who are already taking deucravacitinib, a daily pill that calms the immune system. Researchers will track how well the drug controls skin symptoms, its side effects, and how it affects quality of life in re…

This early-stage trial is testing several new drug combinations, including an experimental drug called CC-92480, in people with multiple myeloma that has come back or stopped responding to treatment. The main goals are to check safety and find the right doses. About 260 participa…

This phase 3 trial tests whether a combination of two drugs, KarXT and KarX-EC, can safely reduce agitation in people with Alzheimer's disease. About 352 adults with Alzheimer's-related agitation will receive either the drug combo or a placebo for 14 weeks. The main goal is to se…

This phase 3 trial tests whether a combination of two drugs, KarXT and KarX-EC, can safely reduce agitation in people with Alzheimer's disease. About 352 adults will receive either the drug combo or a placebo for 14 weeks. The main goal is to see if agitation symptoms improve, as…

This study is testing the long-term safety of a combination of two drugs, KarXT and KarX-EC, for treating agitation in people with Alzheimer's disease. It is an open-label extension, meaning everyone knows they are getting the treatment. The study enrolls 600 participants who hav…

This study tests whether the drug KarXT can reduce symptoms of mania in people with Bipolar I disorder who are currently hospitalized for a manic episode. About 274 participants will receive either KarXT or a placebo for 3 weeks while staying in the hospital. The main goal is to …

This Phase 3 trial is testing whether a combination of two drugs, KarXT and KarX-EC, can improve cognitive impairment in people with mild to moderate Alzheimer's disease. About 586 participants will receive either the drug combo or a placebo. The study measures changes in memory,…

This Phase 3 trial tests whether the drug combination KarXT + KarX-EC can safely reduce psychosis symptoms (like hallucinations and delusions) in people with Alzheimer's disease. About 325 participants aged 55-90 will receive either the drug or a placebo. The study is currently r…

This study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…

This study is a large registry that will follow about 1,700 people with obstructive hypertrophic cardiomyopathy in the US and Europe. Researchers will track how patients respond to mavacamten or other standard treatments in real-world settings, focusing on safety and effectivenes…

This early-stage study is testing new forms of two drugs, KarX and KarT, in 72 healthy adults. Researchers want to see how the body absorbs and processes these new versions compared to the original drugs, and whether food changes their effects. The goal is to gather safety and do…

This study in 140 healthy adults tests how well different tablet versions of the drug BMS-986435 are absorbed into the body and whether taking it with food changes absorption. Participants will receive one or more doses of the drug in different tablet forms. The goal is to pick t…

This study investigates whether the multiple sclerosis medication ozanimod is linked to a higher risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection caused by the John Cunningham virus. Researchers will review reported cases of PML in peop…

This early-stage study tests a new drug called BMS-986533 in 118 healthy adults to see if it's safe and how the body processes it. Researchers will also check if food or stomach acid changes how the drug works, and if it interacts with other medications. Participants will not rec…

This early study tests a new drug called BMS-986521 in 12 healthy adults. Researchers use PET scans to see how much of the drug reaches and attaches to M4 receptors in the brain. The goal is to learn about the drug's action, not to treat any illness. This is a first step before t…

This early-stage study tests whether two different tablet forms of the drug navlimetostat are processed the same way in the body. It involves 64 healthy adult women who are not able to become pregnant. Participants will receive both tablet versions at different times to compare d…

This study follows about 1,182 pregnant women with ulcerative colitis who are taking or have taken ozanimod. Researchers will watch for any health problems in the mothers and their babies, such as birth defects or pregnancy complications. The goal is to learn whether the drug is …

This early-stage study is testing how the drug BMS-986435 behaves in the body and whether it is safe for people with mild to moderate liver problems compared to those with healthy livers. 24 adults will receive a single dose, and researchers will measure drug levels and monitor f…

This early-phase study looks at how a new drug (BMS-986504) moves through and leaves the body in people with advanced solid tumors that have a specific missing gene (MTAP deletion). The main goal is to understand the drug's breakdown and elimination, not to treat the cancer direc…

This study is following about 362 adults with a type of heart disease called obstructive hypertrophic cardiomyopathy who are taking the drug mavacamten. Researchers want to see how the drug works in real doctor's offices, not just in strict research settings. They will track thin…

This study looks at tumor samples from 50 people who developed a second cancer after receiving a Bristol-Myers Squibb CAR-T cell therapy for blood cancers like lymphoma or myeloma. Researchers will test the new tumors for traces of the gene-modified cells used in the original tre…

This early-stage study tests an experimental drug called BMS-986521 in healthy adults to see if it is safe and how the body processes it. About 106 participants will receive either the drug or a placebo. The study does not aim to treat any disease; it is designed to gather import…

This study follows about 1,200 pregnant women with multiple sclerosis who take the drug ZEPOSIA (ozanimod). Researchers will track health outcomes for mothers and their babies, such as birth defects and pregnancy complications. The goal is to help patients and doctors make inform…

This observational study is looking at the safety of the heart medication mavacamten when taken during pregnancy or while breastfeeding. Researchers will follow about 20 people who have taken at least one dose of mavacamten during pregnancy or breastfeeding, tracking outcomes for…